A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster ...

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...

Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) ...

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

Osteoarthritis (OA) is one of the most prevalent conditions affecting tens of millions of U.S. adults, traditionally ...

pennmedicine.upenn.edu Background/aims Glucagon-like peptide-1 receptor (GLP-1R) agonists regulate blood glucose and are commonly used to treat type 2 diabetes mellitus. Recent work showed that ...

These therapies, including dual GIP and GLP-1 receptor agonists (eg, tirzepatide), triple GIP, GLP-1, and glucagon receptor agonists (eg, retatrutide), and cagrilintide and GLP-1 receptor agonist ...

PL8177 is a potent, selective agonist at the human melanocortin-1 receptor (MC1R), with sub-nanomolar affinity binding and EC50 functional values. Palatin data demonstrates that their oral formulation ...

PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced positive topline results from its ...

Septerna also continues to progress several incretin receptor agonist lead compounds, including single- and multi-acting GLP-1, GIP, or glucagon receptor agonists for the treatment of metabolic ...